z-logo
open-access-imgOpen Access
Animal Models in CRS and Pathophysiologic Insights Gained: A Systematic Review
Author(s) -
Shin HyunWoo
Publication year - 2016
Publication title -
laryngoscope investigative otolaryngology
Language(s) - English
Resource type - Journals
ISSN - 2378-8038
DOI - 10.1002/lio2.29
Subject(s) - animal model , modalities , medicine , therapeutic modalities , disease , medline , chronic rhinosinusitis , human studies , bioinformatics , intensive care medicine , pathology , biology , immunology , social science , biochemistry , sociology
Objective Chronic rhinosinusitis (CRS) is a multifactorial inflammatory disease. In particular, CRS with eosinophilic features and/or nasal polyps (NPs) is often recalcitrant to current treatment; thus, appropriate animal models are mandatory to elucidate the pathogenesis of CRS and develop novel and efficient treatment modalities. The author reviewed the recently proposed animal models in CRS and discussed the pathophysiologic insights gained. Data Sources: Articles in the English language referenced in MEDLINE/PubMed from the year 2006 onward (for last 10 years). Review Methods: Review of the literature regarding animal models and related pathologic insights in CRS. Results Mouse, rabbit, and sheep models of CRS have been used for studying the pathogenesis of CRS. Most of researchers adopted animal models of CRS to prove any molecular mechanisms or therapeutic efficacy. In vitro or human findings and related hypothesis were evaluated in vivo using these models. In addition, novel therapeutic candidates for CRS with or without NP have been applied to animal models. Conclusion Animal models have elicited insights into the pathogenesis of CRS and also have been useful in testing new treatment modalities. Although there are still clear limitations in the animal studies, newly proposed or revised animal models would be helpful to understand the exact pathophysiology of CRS

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here